Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2000
11/23/2000WO2000069412A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
11/23/2000WO2000069257A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000036090A3 Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000DE19923027A1 Verfahren zur Inaktivierung von Viren A method of inactivating viruses
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374297A1 Furanone derivatives as inhibitors of cathepsin s
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374013A1 Protein a based binding domains with desirable activities
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373616A1 Tm4sf receptors
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373610A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
11/23/2000CA2373532A1 Morpholino-n-ethyl ester derivative of an indole spla2 inhibitor
11/23/2000CA2373509A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372617A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2368620A1 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053754A1 Method of inactivating viruses
11/22/2000EP1053351A1 Novel molecules of the tnf receptor superfamily and uses therefor
11/22/2000EP1053332A1 Protein
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053245A1 45 human secreted proteins
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053029A1 Sterile complex of therapeutic peptide bond to a polysaccharide
11/22/2000EP1053027A1 Bibapcitide-based pharmaceutical compositions for imaging and treating thrombi
11/22/2000EP1053004A2 Use of angiotensin analogues for promoting erythropoiesis
11/22/2000EP0669936B1 Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
11/22/2000CN1274350A Efficient method for conversion of nitriles to amidines
11/22/2000CN1274288A Peptide-containing & alpha; -ketoamide cysteine and serine protease inhibitors
11/22/2000CN1274283A Quinoline-containing & Alpha;-ketoamide cysteine and serine protease inhibitors
11/22/2000CN1274281A Compsns. for treating and preventing arterial thrombosis and use of factor Xa inhibitor on its own and/or combined with platelet antiaggegating agent
11/22/2000CN1273860A Medicine for treating blood vessel embolism and its preparing process
11/22/2000CN1273822A Oral liquid of L-arginine for treating cardiovascular and cerebrovascular diseases and its preparing process
11/22/2000CN1058616C Compound medicine for treating hemophilia and producing tech. thereof
11/21/2000US6150402 Natriuretic compounds
11/21/2000US6150382 Enzyme inhibitors of blood coagulation factor xa, a serine protease class of enzymes; e.g., 4-hydroxy-3-((4-(2-carboxy-methyl)thio-6-(3-(1-methyl)-6-(3-(1 -methyl)imidazolin-2-yl)-phenoxy-3,5-difluoropyridine and derivatives
11/21/2000US6150378 Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
11/21/2000US6150348 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
11/21/2000US6150329 Multimeric antithrombotic agents
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000CA2117528C Facilitated oxygen delivery in conjunction with hemodilution
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068377A1 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
11/16/2000WO2000068376A1 Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
11/16/2000WO2000068264A2 A peptide inhibitor of fibrinogen blood clotting
11/16/2000WO2000068254A1 Spray drying of thrombin inhibitors
11/16/2000WO2000068246A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000WO2000068226A1 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068188A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067789A1 High concentration immunoglobulin preparation and method for its production
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067759A1 Novel, specific inhibitors of acute and chronic inflammation
11/16/2000WO2000067727A1 Galenic formulations of antithrombotic agents for subcutaneous administration
11/16/2000WO2000048996A3 β-ALANINE DERIVATIVES
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000039285A3 Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000DE19921346A1 Sprühtrocknung von Thrombininhibitoren Spray drying of thrombin inhibitors
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373068A1 Spray drying of thrombin inhibitors
11/16/2000CA2373052A1 Novel, specific inhibitors of acute and chronic inflammation
11/16/2000CA2373010A1 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000CA2372515A1 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
11/16/2000CA2369605A1 Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/15/2000EP1051620A1 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
11/15/2000EP1051521A2 Method of screening therapeutic agents
11/15/2000EP1051431A1 Thrombin inhibitors
11/15/2000EP1051429A1 Ldl related protein and uses thereof
11/15/2000EP1051399A1 Phenylalanine derivatives useful as pharmaceutical agents
11/15/2000EP1051398A1 Thermodynamically stable form of (r)-3- (4-fluorophenyl) sulphonyl]amino] -1,2,3,4- tetrahydro -9h-carbazole -9-propanoic acid (ramatroban)
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051188A1 Mucosal delivery system comprising lipophilic thrombin inhibitors
11/15/2000EP1051183A1 Peritoneal dialysis solution containing modified icodextrins
11/15/2000EP1051176A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/15/2000EP0658168B1 Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
11/15/2000CN1273099A Exterior-applied medicine for treating scald and its preparing process
11/14/2000US6147080 Inhibitors of p38
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/14/2000US6146837 Detecting fc gamma receptor (cd64) in a biological sample by conacting sample with cyanin compound, cy5; illuminating the sample with light of an appropriate excitation wavelength; and detecting fluorescence
11/14/2000US6146623 A gene therapy for treating cancer
11/14/2000CA2074839C Modified factor vii anticoagulant proteins
11/09/2000WO2000066754A1 Protein c derivatives
11/09/2000WO2000066753A2 Modified vitamin k-dependent polypeptides
1 ... 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 ... 671